Illumina has recently advanced its plan to divest its cancer-diagnostics unit, a move intended to ease regulatory pressure and sharpen its focus on core DNA sequencing and microarray technologies.

The Genomics Core offers a variety of microarray analysis options for DNA and epigenetic studies. The Illumina BeadArray technology combined with the Illumina iScan Array Scanner allows for analysis ...

Michael Ryskin, an analyst from Bank of America Securities, maintained the Sell rating on Illumina (ILMN – Research Report). The associated price target remains the same with $105.00. Michael Ryskin’s ...

RBC Capital analyst Conor McNamara maintained a Buy rating on Illumina (ILMN – Research Report) yesterday and set a price target of $242.00. The company’s shares closed last Friday at $104.38.

Illumina's (NASDAQ: ILMN) first-quarter results were full of exclamation points -- at least from an investor's perspective. Revenue jumped nearly 31% year over year. Adjusted earnings per share more ...

Despite recent challenges, Illumina rebounds with strong preliminary Q4 results, led by the successful NovaSeq X launch and strategic alliances, positioning itself as a key player in the genomics ...